You are here: Industry Insights > ADC

News List

Innovent Biologics Signs License Agreement with Synaffix contractpharma
July 02, 2021
Synaffix will provide proprietary ADC technologies to enable Innovent to rapidly progress one of its antibodies as a best-in-class ADC candidate.
Innovent Announces License Agreement with Synaffix in an ADC Technology Deal prnasia
June 29, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced the signing of ...
Iksuda, LegoChem Expand ADC Alliance contractpharma
June 23, 2021
Grants Iksuda access to LegoChem's next generation ADC platform for up to six targets.
Eisai, BMS Enter Global Anticancer ADC Alliance contractpharma
June 21, 2021
Eisai Co., Ltd. and Bristol-Myers Squibb Co. entered an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC).
VERAXA and Quadira Enter ADC Development Partnership contractpharma
June 16, 2021
VERAXA Biotech GmbH (former Velabs Therapeutics GmbH), an ADC engineering and functional antibody screening company, has entered into a partnership with Quadira Biosciences AG of Zug, Switzerland, to develop a suite of novel ADCs for the treatment of ...
WuXi XDC and LegoChem Ink ADC Agreement contractpharma
June 15, 2021
WuXi XDC, a global CDMO providing end-to-end bioconjugates services, and LegoChem Biosciences (LCB), signed a Memorandum of Understanding (MOU) for a partnership in development and manufacturing of antibody-drug conjugates (ADCs).
VERAXA Biotech and Quadira Biosciences Enter Partnership on ADC Development b3cnewswire
June 15, 2021
VERAXA Biotech GmbH (former Velabs Therapeutics GmbH), announced today that it has entered into a partnership agreement with Quadira Biosciences AG, Zug, Switzerland， to jointly develop a suite of novel ADCs for the treatment of oncological conditions.
Iksuda Therapeutics raises $47m to progress ADC pipeline pharmatimes
June 08, 2021
Newcastle, UK-headquartered Iksuda Therapeutics has announced the closing of a $47m (£34m) financing round, with the funds to be used to support the advancement of its lead antibody drug conjugate (ADC) assets.
Pandemic inevitably slows pharma M&A activity but appetite for deals remains cphi-online
June 07, 2021
The initial outbreak of the COVID-19 pandemic delayed merger and acquisitions in the pharma sector, but evidence points to an uptick in activity because the rationale for sealing deals hasn’t changed
Avid Bioservices to Manufacture Zynlonta for ADC Therapeutics contractpharma
May 26, 2021
Avid Bioservices Inc., a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing development and manufacturing services to biotechnology and pharmaceutical companies, will serve as ...

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page